Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilities whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Numans Health Food Holdings Company Limited
紐曼思健康食品控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2530)

SUPPLEMENTAL ANNOUNCEMENT
CHANGE OF COMPLIANCE ADVISER

Reference is made to the announcement of Numans Health Food Holdings Company Limited (the "**Company**") dated 9 March 2026 (the "**Announcement**") in relation to the change of compliance adviser of the Company. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

In addition to the information set out in the Announcement, the Company would like to provide the Shareholders and potential investors of the Company with the following additional information in respect of the change of compliance adviser.

FURTHER INFORMATION ON THE CHANGE OF COMPLIANCE ADVISER

Chronology of principal events of change of compliance adviser

Date	Event
Early January 2026	The management of Company noted that the compliance advisory service by Caitong has lasted for one year since January 2025 when the Company was listed on the Stock Exchange. In view that there were no significant compliance issues related to the Company in 2025, the Company considered it would be in the interests of the Company and its shareholders to look for compliance advisory services that can save costs (but without compromising service quality) of the Company going forward. Following which, the chief financial officer and Company secretary of the Company initiated a discussion with the representatives of Caitong on the possible fee reduction of the compliance advisory service for the remaining tenure (which was then expected to complete in April 2027).

Date	Event
Between January 2026 and 2 March 2026	Various communications between the Company and Caitong on the possible fee reduction took place in January and February 2026. In view no agreement could be reached on fee reduction and considering the possible termination of services by Caitong, the Company sought fee quote from Innovax for the compliance advisory service for the remaining tenure. While Caitong was in the position that the fee in respect of its compliance advisory services should not be reduced, Innovax, on the other hand, offered a more competitive fee quote in respect of the proposed compliance advisory services. The Board noted that Innovax is a licensed corporation permitted to carry out Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), with two responsible officers being assigned for acting as the principal contact points with the Company and (where necessary) the Stock Exchange, and is able to perform the role of compliance adviser of the Company and had prior experience of acting as compliance adviser of more than seven listed companies in Hong Kong during the period from 1 January 2024 to 9 March 2026, being the date of announcement in relation to the change of compliance adviser of the Company. Subsequently, between February and March 2026, Innovax conducted several rounds of communications with the Company's representatives. To familiarise itself with the Company's operations and business model, Innovax thoroughly reviewed all published announcements and documents issued by the Company since its listing, including, but not limited to, the Company's prospectus, its annual report for the year ended 31 December 2024, and its interim report for the six months ended 30 June 2025. The Company also noted that Innovax has 13 responsible officers and 5 representatives for Type 6 (advising on corporate finance) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), and is of the view that Innovax has a larger pool of support for compliance of Listing Rule by the Company going forward. In view of the above, the Board considered that Innovax possessed the relevant experience, qualification and resources to perform the duties of the Company's compliance adviser going forward.

Date	Event
Late February 2026 and on 27 February 2026	Following several round of discussions on fees and timing of resignation between the Company and Caitong, Caitong tendered its resignation as compliance adviser on 27 February 2026, with effect from 9 March 2026.
Early March 2026	The Company then reached a preliminary agreement with Innovax on the terms of the compliance advisory service. On 2 March 2026, the Company confirmed with Caitong on its resignation to take effect from 9 March 2026. On 9 March 2026, the Company entered into the compliance adviser agreement with Innovax with effect from 10 March 2026.
9 March 2026	The Announcement was issued.

Compliance with the Listing Rules

Caitong tendered its termination of the compliance adviser agreement on 27 February 2026, and the Company acknowledged and accepted such termination on 2 March 2026, with the termination to take effect from 9 March 2026. On 2 March 2026, the Company confirmed the new engagement with Innovax as its replacement compliance adviser with effect from 10 March 2026. Following which, the Company communicated with, amongst others, the professional parties including Caitong and Innovax respectively on finalizing the draft Announcement and published the Announcement on 9 March 2026. In addition, the Company had consulted Caitong, and Caitong had advised the Company that a replacement compliance adviser must be appointed by the listed issuer within three months of the effective date of resignation or termination as stipulated in Rule 3A.27 of the Listing Rules. Caitong had also reminded the Company of its disclosure obligations and requirements pursuant to Rules 3A.29 and 13.51(6) of the Listing Rules.

In light of the above, the Board is of the view that the Company has duly complied with Rule 3A.23 of the Listing Rules, and Caitong has discharged its responsibilities with due care and skill as required under Rule 3A.24 of the Listing Rules by ensuring the Company is properly guided and advised as to compliance with the Listing Rules in respect of the change of compliance adviser.

As the dispute of fee between the Company and Caitong began in early January 2026 and it was not resolved up to the date of formal resignation of Caitong which has been over 30 days, the Board considers that the termination of compliance adviser agreement fell into circumstances under Rule 3A.26 of the Listing Rules.

Factors considered by the Company in relation to appointing Innovax as compliance adviser of the Company

In considering Innovax as the Company's compliance adviser, the Company has taken into account of, amongst others, (i) the experience of Innovax in provision of compliance advisory services for other listed issuers, in particular, in the past two years; (ii) the manpower (including the number of responsible officers and licensed representatives and seniority of the contact points of Innovax) undertaken to be devoted in providing to the Company for the compliance advisory services; (iii) the proposed scope of services by Innovax via-a-vis the scope of works of a compliance adviser as required under Rule 3A.23 of the Listing Rules; and (iv) the service fees proposed by Innovax, and is of the view that Innovax is a suitable candidate for the role of compliance adviser of the Company.

In light of the above, the Board is of the view that the scope of compliance advisory services provided by Innovax is no less than the scope of services rendered by Caitong, and the quality of compliance advisory services provided by Innovax will not be affected by the lower service fees proposed by Innovax.

All other information contained in the Announcement remains unchanged and continues to be valid for all purposes. This announcement is a supplement to and should be read in conjunction with the Announcement.

By Order of the Board
Numans Health Food Holdings Company Limited
Wang Ping
Chairman

Hong Kong, 17 April 2026

As at the date of this announcement, the Board comprises Mr. Wang Ping and Ms. Cui Juan as executive Directors, Mr. Chan Hok Leung as non-executive Director, and Ms. Yim Wing Yee, Mr. Lau Kwok Fai Patrick and Mr. Yu Tsz Ngo as independent non-executive Directors.